The effectiveness, cost-effectiveness, budget impact, and return on investment of scaling up tuberculosis screening and preventive treatment in Brazil, Georgia, Kenya, and South Africa: a modelling study

Journal:

The Lancet Global Health

Published:

2025-10-16

DOI:

10.1016/s2214-109x(25)00321-3

Affiliations:

26

Authors:

28

Go to article

Institutions	Authors	Share
World Health Organization (WHO), Switzerland	4.500000	0.16
McGill University, Canada	3.416667	0.12
Brazil Ministry of Health, Brazil	3.000000	0.11
National Center of Tuberculosis and Lung Disease (NCTLD), Georgia	2.000000	0.07
Kenya Ministry of Health, Kenya	2.000000	0.07
University of the Witwatersrand, Johannesburg (Wits University), South Africa	1.500000	0.05
Futures Health Economics and Metrics (F.H.E.M), Kenya	1.500000	0.05
South Africa Department of Health (DOH), South Africa	1.500000	0.05
Imperial College London (ICL), United Kingdom (UK)	1.000000	0.04
Federal University of Rio de Janeiro (UFRJ), Brazil	1.000000	0.04
National Center for Disease Control and Public Health (NCDC), Georgia	1.000000	0.04
McGill University Health Centre (MUHC), Canada	0.583333	0.02
UK Health Security Agency, United Kingdom (UK)	0.500000	0.02
TBpeople Canada, Canada	0.500000	0.02
University of California, Santa Cruz (UCSC), United States of America (USA)	0.500000	0.02
David Tvildiani Medical University (DTMU), Georgia	0.500000	0.02
Boston University (BU), United States of America (USA)	0.500000	0.02
European University, Georgia, Georgia	0.500000	0.02
University of Nairobi, Kenya	0.500000	0.02
The Aurum Institute, South Africa	0.500000	0.02
Federal University of Mato Grosso do Sul (UFMS), Brazil	0.333333	0.01
Oswaldo Cruz Foundation (FIOCRUZ), Brazil	0.333333	0.01
Yale University, United States of America (USA)	0.333333	0.01

Interested in Policy and Administration?